Estimating recurrences prevented and costs avoided with atezolizumab in early non-small cell lung cancer in the United States.
Rishika SharmaSarika OgaleNathaniel J SmithJanet Shin LeePublished in: Cancer medicine (2022)
Adjuvant ATZ is estimated to prevent a significant number of recurrences and reduce the economic burden of eNSCLC.
Keyphrases